HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...

MASH has long been a challenging and progressive liver disease, characterized by fat build-up and inflammation that, if left ...

Noureddin et al. (2024). Clin Gastroenterol Hepatol, 22(12), 2367-2377. (*consistent with stages F2 to F3 fibrosis, also referred to in the literature as "MASH with significant fibrosis," "MASH ...

In the phase 3 target population of people with F2-F3 disease, where the liver has ... At high dose there was a significant improvement of fibrosis by at least one stage without worsening of ...

With FibroSIGHT, we aim to empower clinicians with a more definitive and accurate assessment of liver fibrosis." MASH has long been a challenging and progressive liver disease, characterized by ...

A solid emerging-markets option. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform a relevant index, or most peers, over a market cycle on a ...

Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an ...

Background Intestinal fibrosis resulting in stricture formation and obstruction in Crohn’s disease (CD) and increased wall stiffness leading to symptoms in ulcerative colitis (UC) is among the largest ...

Correspondence to Isabelle Touitou, Unité médicale des maladies autoinflammatoires, CHRU Montpellier, INSERM U844, Université UM1, Montpellier, France; isabelle.touitou{at}inserm.fr Hereditary ...